Bladder Cancer Research Results and Study Updates
See Advances in Bladder Cancer Research for an overview of recent findings and progress, plus ongoing projects supported by NCI.
For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to BCGPosted:
The standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC), a drug called BCG, has been in shortage for a decade. Bladder cancer experts agree that gemcitabine and docetaxel offers an effective alternative to BCG, after a study showed that 82% of patients with high-risk NMIBC treated with the combination were alive 2 years later without their cancer returning.
Study Clarifies Timing of Immunotherapy for Advanced Bladder CancerPosted:
Results from a large study show that, for most people with advanced bladder cancer, starting immunotherapy with avelumab (Bavencio) shortly after initial treatment with chemotherapy is better than delaying treatment.
Enfortumab Vedotin Approved for Recurrent Bladder CancerPosted:
Enfortumab vedotin-ejfv (Padcev) has been approved for people with advanced bladder cancer. FDA granted the drug accelerated approval for cancers that have progressed despite previous treatments.
Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder CancerPosted:
New clinical trial findings confirm that the targeted therapy erdafitinib (Balversa) can benefit patients with advanced bladder cancer whose tumors have a genetic alteration in one of the four FGFR genes.
FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder CancerPosted:
FDA has changed the approved uses of the immunotherapy drugs pembrolizumab (Keytruda) and atezolizumab (Tecentriq) to treat the most common form of bladder cancer. The change is based on whether patients’ tumors have a specific biomarker.
New Treatment Approach Could Help Prevent Recurrences of Some Bladder CancersPosted:
Flushing the bladder with the chemotherapy drug gemcitabine after tumors have been removed surgically may reduce the risk of low-grade bladder cancer returning, according to the results of a large clinical trial.
FDA Approves Immunotherapy Drugs for Patients with Bladder CancerPosted:
The FDA has approved four immunotherapy drugs—avelumab, atezolizumab, durvalumab, and pembrolizumab—for the treatment of patients with bladder cancer. All four drugs belong to a class of cancer therapies known as checkpoint inhibitors.
FDA Approves Nivolumab for Bladder CancerPosted:
The FDA has approved nivolumab for the treatment of unresectable locally advanced or metastatic bladder cancer that worsened after treatment with platinum-based chemotherapy.
FDA Approves New Immunotherapy Drug for Bladder CancerPosted:
The FDA has approved atezolizumab (Tecentriq®) for the treatment of some patients with urothelial carcinoma, the most common type of bladder cancer.
Elevated bladder cancer risk in New England and arsenic in drinking water from private wellsPosted:
A new study has found that drinking water from private wells, particularly dug wells established during the first half of the 20th century, may have contributed to the elevated risk of bladder cancer that has been observed in Maine, New Hampshire, and Vermont for over 50 years.